Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation

被引:440
作者
Finch, Amy
Beiner, Mario
Lubinski, Jan
Lynch, Henry T.
Moller, Pal
Rosen, Barry
Murphy, Joan
Ghadirian, Parviz
Friedman, Eitan
Foulkes, William D.
Kim-Sing, Charmaine
Wagner, Teresa
Tung, Nadine
Couch, Fergus
Stoppa-Lyonnet, Dominique
Ainsworth, Peter
Daly, Mary
Pasini, Babara
Gershoni-Baruch, Ruth
Eng, Charis
Olopade, Olufunmilayo I.
McLennan, Jane
Karlan, Beth
Weitzel, Jeffrey
Sun, Ping
Narod, Steven A.
机构
[1] Toronto Sunnybrook Reg Canc Ctr, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada
[2] Pomeranian Med Univ, Szczecin, Poland
[3] Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA
[4] Norwegian Radium Hosp, Oslo, Norway
[5] Univ Toronto, Dept Gynecol Oncol, Univ Hlth Network, Toronto, ON, Canada
[6] Univ Montreal, CHUM Hotel Dieu, Dept Med, Epidemiol Res Unit, Montreal, PQ, Canada
[7] Univ Montreal, CHUM Hotel Dieu, Dept Genet, Epidemiol Res Unit, Montreal, PQ, Canada
[8] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[9] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
[10] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[11] Med Univ Vienna, Div Senol, Vienna, Austria
[12] Private Trust Breast Hlth, Vienna, Austria
[13] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[14] Mayo Clin Coll Med, Rochester, MN USA
[15] Inst Marie Curie, Paris, France
[16] London Reg Canc Program, London, ON, Canada
[17] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[18] Univ Turin, I-10124 Turin, Italy
[19] Rambam Med Ctr, Haifa, Israel
[20] Ohio State Univ, Columbus, OH 43210 USA
[21] Cleveland Clin, Genome Med Inst, Cleveland, OH 44106 USA
[22] Univ Chicago, Chicago, IL 60637 USA
[23] Canc Risk Program, San Francisco, CA USA
[24] Cedars Sinai Med Ctr, Div Gynecol Oncol, Los Angeles, CA 90048 USA
[25] City Hope Med Ctr, Duarte, CA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 02期
关键词
D O I
10.1001/jama.296.2.185
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Women with BRCA1 or BRCA2 mutation are often advised to undergo preventive oophorectomy. The effectiveness of this intervention has not been prospectively evaluated in a large cohort. Objectives To estimate the incidence of ovarian, fallopian tube, and primary peritoneal cancer in women who carry a deleterious mutation in BRCA1 or BRCA2. To estimate the reduction in risk of these cancers associated with a bilateral prophylactic salpingo-oophorectomy. Design, Setting, and Participants Women known to carry a BRCA1 or BRCA2 mutation were identified from an international registry between 1992 and 2003. A total of 1828 carriers at 1 of 32 centers in Canada, the United States, Europe, and Israel completed questionnaires at baseline and follow-up. Participants were observed from the date of study entry until: diagnosis of ovarian, fallopian tube, or peritoneal cancer; death; or the date of the most recent follow-up. Intervention Participants were divided into women who had undergone bilateral prophylactic oophorectomy and those who had not. Main Outcome Measure The incidence of ovarian, peritoneal, and fallopian tube cancer was determined by survival analysis. The risk reduction associated with prophylactic salpingo-oophorectomy was evaluated by a time-dependent survival analysis, adjusting for covariates. Results After a mean follow-up of 3.5 years, 50 incident ovarian, fallopian tube, and peritoneal cancer cases were reported in the cohort. Of the 1828 women, 555 (30%) underwent a bilateral prophylactic salpingo-oophorectomy prior to study entry, 490 (27%) underwent the procedure after entering the study, and 783 (43%) did not undergo the procedure. There were 32 incident cancers diagnosed in women with intact ovaries (1015/100 000 per year). Eleven cancer cases were identified at the time of prophylactic oophorectomy and 7 were diagnosed following prophylactic oophorectomy (217/100 000 per year). The estimated cumulative incidence of peritoneal cancer is 4.3% at 20 years after oophorectomy. The overall ( adjusted) reduction in cancer risk associated with bilateral oophorectomy is 80% (multivariate hazard ratio = 0.20; 95% confidence interval, 0.07-0.58; P=.003). Conclusion Oophorectomy is associated with reduced risk of ovarian and fallopian tube cancer in high-risk women, although there is a substantial residual risk for peritoneal cancer in BRCA1 and BRCA2 mutation carriers following prophylactic salpingooophorectomy.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 25 条
  • [1] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [2] CHEN KTK, 1985, OBSTET GYNECOL, V66, pS93
  • [3] Peritoneal lavage cytology: An assessment of its value during prophylactic oophorectomy
    Colgan, TJ
    Boerner, SL
    Murphy, J
    Cole, DEC
    Narod, S
    Rosen, B
    [J]. GYNECOLOGIC ONCOLOGY, 2002, 85 (03) : 397 - 403
  • [4] Breast cancer risk following bilateral oophorectorny in BRCA1 and BRCA2 mutation carriers:: An international case-control study
    Eisen, A
    Lubinski, J
    Klijn, J
    Moller, P
    Lynch, HT
    Offit, K
    Weber, B
    Rebbeck, T
    Neuhausen, SL
    Ghadirian, P
    Foulkes, WD
    Gershoni-Baruch, R
    Friedman, E
    Rennert, G
    Wagner, T
    Isaacs, C
    Kim-Sing, C
    Ainsworth, P
    Sun, P
    Narod, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7491 - 7496
  • [5] Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
    Finch, A
    Shaw, P
    Rosen, B
    Murphy, J
    Narod, SA
    Colgan, TJ
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 100 (01) : 58 - 64
  • [6] Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
    Ford, D
    Easton, DF
    Stratton, M
    Narod, S
    Goldgar, D
    Devilee, P
    Bishop, DT
    Weber, B
    Lenoir, G
    Chang-Claude, J
    Sobol, H
    Teare, MD
    Struewing, J
    Arason, A
    Scherneck, S
    Peto, J
    Rebbeck, TR
    Tonin, P
    Neuhausen, S
    Barkardottir, R
    Eyfjord, J
    Lynch, H
    Ponder, BAJ
    Gayther, SA
    Birch, JM
    Lindblom, A
    Stoppa-Lyonnet, D
    Bignon, Y
    Borg, A
    Hamann, U
    Haites, N
    Scott, RJ
    Maugard, CM
    Vasen, H
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) : 676 - 689
  • [7] Greene FL., 2002, AJCC CANC STAGING HD, V6th
  • [8] Cancer risks in first degree relatives of BRCA1 mutation carriers:: effects of mutation and proband disease status
    Gronwald, J
    Huzarski, T
    Byrski, B
    Medrek, K
    Menkiszak, J
    Monteiro, AN
    Sun, P
    Lubinski, J
    Narod, SA
    [J]. JOURNAL OF MEDICAL GENETICS, 2006, 43 (05) : 424 - 428
  • [9] Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff, ND
    Satagopan, JM
    Robson, ME
    Scheuer, L
    Hensley, M
    Hudis, CA
    Ellis, NA
    Boyd, J
    Borgen, PI
    Barakat, RR
    Norton, L
    Offit, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) : 1609 - 1615
  • [10] Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
    King, MC
    Marks, JH
    Mandell, JB
    [J]. SCIENCE, 2003, 302 (5645) : 643 - 646